Lower net result than 95% of companies in head offices and management consultancy. Sector median €26,440 · 41,264 companies.
Turnover not published in the micro format
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 12,344 companies had the same profile as PHARMACON has now. Each dot stands for 31 companies, two years later.
90.1%
were still trading
8.7%
stopped another way
0.7%
went bankrupt
Micro
20 years or older
solvency 30% or more
a small loss
Another 0.5% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
2.9%
3.1%
10
5.6%
6.1%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 12,344 companies, not a prediction for PHARMACON. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0457066176
Change of role: Name after signing inVisible after signing in, from director to statutory director
Director discharge: Name hiddenVisible after signing in · General meeting of 12-05-2021 · Gazette deed
Registered office moved from Landegem to Ghent
The registered office moved from Stationsstraat 32- 9850 LANDEGEM to Filaturastraat 20/301 te 9000 GENT · General meeting of 01-08-2018 · Gazette deed
First establishment
At the time the registered office was still in Landegem, Stationsstraat 32.
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as PHARMACON: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €345,000 and €436,000, founded between 1994 and 2001.